Literature DB >> 19386715

Identification of varicella-zoster virus-specific CD8 T cells in patients after T-cell-depleted allogeneic stem cell transplantation.

Pim L J van der Heiden1, Renate de Boer, Dirk M van der Steen, Michel G D Kester, Menno W A G van der Hoorn, Wilmy M E Haarman, Helen E Barnby-Porritt, Jeremy W Fry, C E Napper, Erik W A Marijt, Roel Willemze, J H Frederik Falkenburg, Mirjam H M Heemskerk.   

Abstract

To study the role of CD8 T cells in the control of varicella-zoster virus (VZV) reactivation, we developed multimeric major histocompatibility complexes to identify VZV-specific CD8 T cells. Potential HLA-A2 binding peptides from the putative immediate-early 62 protein (IE62) of VZV were tested for binding, and peptides with sufficient binding capacity were used to generate pentamers. Patients with VZV reactivation following stem cell transplantation were screened with these pentamers, leading to the identification of the first validated class I-restricted epitope of VZV. In 42% of HLA-A2 patients following VZV reactivation, these IE62-ALW-A2 T cells could be detected ex vivo.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19386715      PMCID: PMC2704790          DOI: 10.1128/JVI.02662-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  14 in total

Review 1.  SYFPEITHI: database for MHC ligands and peptide motifs.

Authors:  H Rammensee; J Bachmann; N P Emmerich; O A Bachor; S Stevanović
Journal:  Immunogenetics       Date:  1999-11       Impact factor: 2.846

2.  Peptide-MHC class I tetrameric complexes display exquisite ligand specificity.

Authors:  S R Burrows; N Kienzle; A Winterhalter; M Bharadwaj; J D Altman; A Brooks
Journal:  J Immunol       Date:  2000-12-01       Impact factor: 5.422

3.  Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome.

Authors:  Y Koc; K B Miller; D P Schenkein; J Griffith; M Akhtar; J DesJardin; D R Snydman
Journal:  Biol Blood Marrow Transplant       Date:  2000       Impact factor: 5.742

4.  Equivalent recognition of a varicella-zoster virus immediate early protein (IE62) and glycoprotein I by cytotoxic T lymphocytes of either CD4+ or CD8+ phenotype.

Authors:  A M Arvin; M Sharp; S Smith; C M Koropchak; P S Diaz; P Kinchington; W Ruyechan; J Hay
Journal:  J Immunol       Date:  1991-01-01       Impact factor: 5.422

5.  Nuclear accumulation of IE62, the varicella-zoster virus (VZV) major transcriptional regulatory protein, is inhibited by phosphorylation mediated by the VZV open reading frame 66 protein kinase.

Authors:  P R Kinchington; K Fite; S E Turse
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

6.  Immunity to varicella-zoster viral glycoproteins, gp I (gp 90/58) and gp III (gp 118), and to a nonglycosylated protein, p 170.

Authors:  A M Arvin; E Kinney-Thomas; K Shriver; C Grose; C M Koropchak; E Scranton; A E Wittek; P S Diaz
Journal:  J Immunol       Date:  1986-08-15       Impact factor: 5.422

7.  Clinical relevance of quantitative varicella-zoster virus (VZV) DNA detection in plasma after stem cell transplantation.

Authors:  J S Kalpoe; A C M Kroes; S Verkerk; E C J Claas; R M Y Barge; M F C Beersma
Journal:  Bone Marrow Transplant       Date:  2006-05-22       Impact factor: 5.483

8.  Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region.

Authors:  Mirjam H M Heemskerk; Manja Hoogeboom; Roelof A de Paus; Michel G D Kester; Menno A W G van der Hoorn; Els Goulmy; Roel Willemze; J H Frederik Falkenburg
Journal:  Blood       Date:  2003-07-17       Impact factor: 22.113

9.  Development of virus-specific CD4+ T cells on reexposure to Varicella-Zoster virus.

Authors:  Mireille T M Vossen; Mi-Ran Gent; Jan F L Weel; Menno D de Jong; René A W van Lier; Taco W Kuijpers
Journal:  J Infect Dis       Date:  2004-05-26       Impact factor: 5.226

10.  Persistent high frequencies of varicella-zoster virus ORF4 protein-specific CD4+ T cells after primary infection.

Authors:  Louise Jones; Antony P Black; Gathsaurie N Malavige; Graham S Ogg
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

View more
  5 in total

1.  Metabolic Phenotypes of Response to Vaccination in Humans.

Authors:  Shuzhao Li; Nicole L Sullivan; Nadine Rouphael; Tianwei Yu; Sophia Banton; Mohan S Maddur; Megan McCausland; Christopher Chiu; Jennifer Canniff; Sheri Dubey; Ken Liu; ViLinh Tran; Thomas Hagan; Sai Duraisingham; Andreas Wieland; Aneesh K Mehta; Jennifer A Whitaker; Shankar Subramaniam; Dean P Jones; Alessandro Sette; Kalpit Vora; Adriana Weinberg; Mark J Mulligan; Helder I Nakaya; Myron Levin; Rafi Ahmed; Bali Pulendran
Journal:  Cell       Date:  2017-05-11       Impact factor: 41.582

2.  Varicella-Zoster Virus-Specific Cellular Immune Responses to the Live Attenuated Zoster Vaccine in Young and Older Adults.

Authors:  Adriana Weinberg; Jennifer Canniff; Nadine Rouphael; Aneesh Mehta; Mark Mulligan; Jennifer A Whitaker; Myron J Levin
Journal:  J Immunol       Date:  2017-06-12       Impact factor: 5.422

3.  Immunological evasion of immediate-early varicella zoster virus proteins.

Authors:  Pieter Meysman; Dmitry Fedorov; Viggo Van Tendeloo; Benson Ogunjimi; Kris Laukens
Journal:  Immunogenetics       Date:  2016-03-29       Impact factor: 2.846

Review 4.  T-cell immunity to human alphaherpesviruses.

Authors:  Werner J D Ouwendijk; Kerry J Laing; Georges M G M Verjans; David M Koelle
Journal:  Curr Opin Virol       Date:  2013-05-08       Impact factor: 7.090

5.  Increased herpes zoster risk associated with poor HLA-A immediate early 62 protein (IE62) affinity.

Authors:  Pieter Meysman; Nicolas De Neuter; Esther Bartholomeus; George Elias; Johan Van den Bergh; Marie-Paule Emonds; Geert W Haasnoot; Steven Heynderickx; Johan Wens; Nele R Michels; Julien Lambert; Eva Lion; Frans H J Claas; Herman Goossens; Evelien Smits; Pierre Van Damme; Viggo Van Tendeloo; Philippe Beutels; Arvid Suls; Geert Mortier; Kris Laukens; Benson Ogunjimi
Journal:  Immunogenetics       Date:  2017-12-01       Impact factor: 3.330

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.